Preprint
18 June 2021
Chua, Kao Ping, Conti, Rena M, Becker, Nora V
View resource
Introduction: Millions of U.S. patients have been hospitalized for COVID-19. After discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. We assessed out-of-pocket spending within 90 days of discharge from COVID-19 hospitalization among privately insured and Medicare Advantage patients.
Methods: In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics ® Plus for Academics Database, a national de-identified claims database. Among privately insured and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we calculated mean out-of-pocket spending for care within 90 days of discharge. For context, we repeated analyses for patients hospitalized for pneumonia.
Results: Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were covered by private...
News (peer reviewed)
17 June 2021
Tsai Y, et al
View resource
The COVID-19 pandemic substantially increased medical care requirements and associated costs in the older fee-for-service (FFS) Medicare beneficiary population in the USA, according to a study published in Annals of Internal Medicine.
Journal Article
4 June 2021
Mitton, Craig,Donaldson, Cam,Dionne, Francois,Peacock, Stuart
View resource
Trade-offs abound in healthcare yet depending on where one stands relative to the stages of a pandemic, choice making may be more or less constrained. During the early stages of COVID-19 when there was much uncertainty, healthcare systems faced greater constraints and focused on the singular criterion of “flattening the curve.” As COVID-19 progressed and the first wave diminished (relatively speaking depending on the jurisdiction), more opportunities presented for making explicit choices between COVID and non-COVID patients. Then, as the second wave surged, again decision makers were more constrained even as more information and greater understanding developed. Moving out of the pandemic to recovery, choice making becomes paramount as there are no set rules to lean back into historical patterns of resource allocation. In fact, the opportunity at hand, when using explicit tools...
Journal Article
18 May 2021
Dias-Godói, Isabella Piassi, Tadeu Rocha Sarmento, Túlio, Afonso Reis, Edna, Peres Gargano, Ludmila, Godman, Brian, de Assis Acurcio, Francisco, Alvares-Teodoro, Juliana, Guerra Júnior, Augusto Afonso, Mariano Ruas, Cristina
View resource
The new coronavirus pandemic has appreciably impacted morbidity and mortality, as well as having an economic impact worldwide. New vaccines are a potential way forward to reduce transmission rates and subsequent infection. In Brazil, vaccines are being distributed via the public sector; however, in the future, they will be available in the private market. Information about consumers’ willingness to pay (WTP) for a hypothetical vaccine against SARS CoV-2 can help future price setting discussions. A cross-sectional study was conducted with consumers in the five regions of Brazil regarding the WTP for a hypothetical vaccine against SARS CoV-2 with a 50% efficacy. A total of 1402 individuals over 18 years of age who declared not having COVID-19 at the time of the survey were interviewed. The acceptability for this hypothetical vaccine was 80.7%. In addition, the amount of WTP by...
Blog post
17 May 2021
Karene Hoi Ting Yeung
,
Wei Aun Yap
,
Logan Brenzel
,
Peter Cowley
,
Nathalie Vande Maele
,
Sarah Alkenbrack
,
Ulla Griffiths
,
Raymond Hutubessy
Preprint
14 May 2021
Farzana Sharmin
View resource
The most severe threat that the Covid-19 pandemic poses to the global economy is the need to choose between human lives and livelihoods. Bangladesh must assess the implications of such impacts on Bangladesh’s macro-financial scenario to maintain the economy’s current high growth trajectory. The paper outlines the major Covid-19 shock wave transmission channels to the four major sectors of the Bangladesh economy. Authorities around the world have taken every precaution possible to halt the spread of the pandemic. An aggregate transmission framework that includes these four sectors is required to contain the impact of Covid-19 can propagate through these sectors and eventually impact macro-financial stability.
Preprint
12 May 2021
Reddy, Krishna P, Fitzmaurice, Kieran P, Scott, Justine A, Harling, Guy,Lessells, Richard J, Panella, Christopher,Shebl, Fatma M, Freedberg, Kenneth A, Siedner, Mark J
View resource
Low- and middle-income countries are implementing COVID-19 vaccination strategies in light of varying and uncertain vaccine efficacies and costs, supply shortages, and resource constraints. We used a microsimulation model to evaluate clinical outcomes and cost-effectiveness of a COVID-19 vaccination program in South Africa. We varied vaccination coverage, pace, acceptance, effectiveness, and cost as well as epidemic dynamics. Providing vaccine to at least 40% of the population and prioritizing accelerated vaccine rollout prevented >9 million infections and >73,000 deaths and reduced costs due to fewer hospitalizations. Further, the vaccination program was cost-saving even at the lowest examined levels of acceptance (50%), effectiveness against infection (20%), effectiveness against symptomatic disease (30%), and effectiveness against severe/critical disease requiring hospitalization...
Preprint
11 May 2021
Rebeira, Mayvis, Nauenberg, Eric
View resource
Background: The economic stimulus package in the United States, which totalled $2.48 trillion, was designed to soften the economic impact of sweeping containment measures including shelter-in-place orders that were put in place to control the COVID-19 pandemic.Methods: In healthcare, interventions are rarely justified simply in terms of the number of lives saved but also in terms of a myriad of other trade-off factors including value-for-money or cost-effectiveness. Cost-effectiveness analysis was therefore conducted as the cost per life-year gained (Cost/LYG) from the containment measures adopted based on several different projections of the baseline number of deaths in the absence of any containment measures. Reductions in premature mortality due to the shutdown (i.e. the difference between years of life lost relative to life expectancy under the shutdown and no shutdown...
Journal Article
5 May 2021
Gorji, Hossein, Arnoldini, Markus, Jenny, David, Hardt, Wolf-Dietrich, Jenny, Patrick
View resource
Relevant pandemic-spread scenario simulations can provide guiding principles for containment and mitigation policies. We devised a compartmental model to predict the effectiveness of different mitigation strategies with a main focus on mass testing. The model consists of a set of simple differential equations considering the population size, reported and unreported infections, reported and unreported recoveries, and the number of COVID-19-inflicted deaths. We assumed that COVID-19 survivors are immune (e.g., mutations are not considered) and that the virus is primarily passed on by asymptomatic and pre-symptomatic individuals. Moreover, the current version of the model does not account for age-dependent differences in the death rates, but considers higher mortality rates due to temporary shortage of intensive care units. The model parameters have been chosen in a plausible range...
Editorial
3 May 2021
Chhatwal, Jagpreet, Postma, Maarten J
View resource
On March 11, 2020, the World Health Organization declared coronavirus 2019 (COVID-19) a global pandemic. Within 1 year of this declaration, at least 2.6 million people have reportedly died from COVID-19. During this time, almost all countries implemented some kind of social restrictions (eg, closure of businesses and mask mandates) to mitigate or suppress the transmission of the SARS-Co-2 virus. These nonpharmaceutical interventions helped reduce COVID-19-related morbidity and mortality, but they also significantly impacted the economy. In the past year, pharmaceutical interventions also have become available, which could change the landscape of COVID-19. Multiple COVID-19 treatments are approved for use that can either reduce morbidity or mortality.1 Recently, several COVID-19 vaccines have become available that are highly effective in preventing COVID-19 serious disease as well...